Pantoprazole-d6 (Synonyms: BY1023-d6; SKF96022-d6) |
| Katalog-Nr.GC45539 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 922727-65-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pantoprazole-d6 is intended for use as an internal standard for the quantification of pantoprazole by GC- or LC-MS. Pantoprazole is a proton pump inhibitor that inhibits H+/K+-ATPase activity in porcine gastric membrane vesicles with an IC50 value of 6.8 μM.1 It reduces basal gastric acid secretion in pylorus-ligated rats (ED50 = 1.3 mg/kg) and inhibits mepirizole-induced increases in gastric acid secretion in an anesthetized rat model of gastric fistula (ED50 = 0.8 mg/kg).2 Pantoprazole inhibits formation of mepirizole-induced duodenal lesions in rats (ED50 = 0.5 mg/kg). Formulations containing pantoprazole have been used in the treatment of gastroesophageal reflux disease (GERD) and hypersecretory conditions, including Zollinger-Ellison Syndrome.
References
1. Beil, W., Staar, U., and Sewing, K.F. Pantoprazole: A novel H+/K+-ATPase inhibitor with an improved pH stability. Eur. J. Pharmacol. 218(2-3), 265-271 (1992).
2. Takeuchi, K., Konaka, A., Nishijima, M., et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole. J. Gastroenterol. Hepatol. 14(3), 251-257 (1999).
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *